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Recent studies have suggested that postoperative bleeding is decreased in pediatric 
heart operations if fresh whole blood instead of blood component therapy is used for 
postoperative transfusions. Because this is in contrast o our practice to use whole 
blood for only the priming of the cardiopulmonary b pass circuit and then to nse 
blood components for additional transfusion requirements, it was our interest to 
analyze the bleeding complications and the use of blood products after heart 
operations in infants. The patient records of the 73 infants operated on in 1992 were 
reviewed. The chest ube drainage varied from 3 to 51 ml/kg per 6 hours (mean 10 
ml/kg) and it did not correlate with any of the tested clinical or laboratory 
parameters. One infant underwent reoperation because of surgical bleeding. Dis- 
seminated intravascular coagulation developed in another patient. Sixty-eight 
patients (93%) needed red blood cell supplementation. Sixty-eight percent of 
patients between 1 month and 1 year old could be treated without any other 
postoperative transfusion except for red blood cell supplementation. I  contrast, in 
the neonates, platelet concentrates or fresh frozen plasma, orboth, were nsed in 61% 
of the patients. In addition to the known immaturity of the hemostatic system, the 
increased need for platelet concentrates in the neonates was attributed to longer 
cardiopulmonary b pass time, deeper hypothermia n association with circulatory 
arrest, larger dosages of heparin, and more extensive plasma dilution during 
cardiopulmonary b pass. In conclusion, a low rate of bleeding complications and 
acceptably low general blood loss can be achieved postoperatively with biood 
component therapy. (J TrlORAC CARDIOVASC SURG 1995;109:524-9) 
Jari Petäjä, MD, Ulla Lundström, MD, Mauri Leijala, MD, Kaija Peltola, MD, 
and Martti A. Siimes, MD, Helsinki, Finland 
C ardiac operations are orten associated with bleeding complications, and resternotomy be- 
cause of bleeding is needed in 3% to 5% of pa- 
tients.1, 2 The cause of bleeding after cardiac oper- 
ations is multifactorial with contributions from 
problems with surgical hemostasis and hemostatic 
alterations involving platelets, coagulation, and fi- 
brinolytic systems. 2-5 
Transfusion requirements in heart operations have 
decreased, 6-s but still blood transfusions constitute 
both remarkable conomic ost and a medical risk of 
adverse reactions including viral infections. However, 
it seems that blood product policies are high/y variable 
in different centers and only partly dependent on 
sound medical indications. 6'9'm Development of 
blood-saving techniques has made heart operations 
possible even without homologous blood transfu- 
sions, n The general development in transfusion med- 
icine including transfusions after cardiac operations 
has been toward use of blood components instead of 
unfractioned blood. However, in pediatric ardiac op- 
erations, the situation is more unclear. In a recent 
study, use of fresh whole blood instead of stored blood 
524 
components after termination f cardiopulmonary b - 
pass (CPB) in children younger than 2 years old 
resulted in a 46% decrease in the postoperative blood 
loss. 12 Later, the use of fresh whole blood was also 
recommended by others. 13'14 In our hospital, the 
transfusion requirements after CPB have almost ex- 
clusively been met with component therapy for several 
years. Therefore it was of interest to analyze the 
bleeding complications and the use of blood products 
in infants less than 1 year old who underwent heart 
operations. In addition it was our aim to characterize 
the potential risk groups of patients with higher trans- 
, s ion  requirements. 
Patients and methods 
The patient series comprised all of the 73 infants, 
younger than 1 year of age, who had initial open heart 
operations in our hospital in 1992. Of them, 23 were 
younger than 4 weeks old and were called neonates. The 
others were called older infants. There were 32 boys and 
41 gifts, Of the patients, 9were born before 38 weeks of 
gestation. 
The cardiac defects of the patients are shown in Table 
I. Standardized surgical and CPB techniques were used 
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with core cooling to 18 ° to 20 ° C. In association with 
circulatory arrest (n = 23) hypothermia varied from 18 ° to 
15 ° C. Cold potassium (5 ° C) crystalloid (n -- 55) or blood 
(n = 18) cardioplegia for myocardial preservation was 
used. In 65 patients, the anesthesia was done by high doses 
of intravenous fentanyl and pancuronium. Whole blood, 
donated 20 to 28 hours before the operation (except for 
operations on Mondays, when the blood was donated on 
the previous Saturday), tested for antibodies against hu- 
man immunodeficiency virus and hepatitis C virus and 
presence of hepatitis B surface antigen, and 4% human 
albumin solution were used for priming of the CPB 
circuit. The dilution was calculated to achieve a hemato- 
crit of 25%. The whole volume of cardioplegia was 
hemofiltrated and during rewarming the hematocrit value 
was elevated to the target value by adding whole blood to 
the CPB circuit and continuing the hemofiltration. Occa- 
sionally, red blood cell concentrates (RBCs) were used in 
addition to the whole blood, if the target hematocrit was 
not achieved conveniently with whole blood and hemofil- 
tration. 
During CPB 10 patients needed less than 500 ml of 
whole blood (1 donor), 62 between 500 and 1000 ml (2 
donors), and 1 patient more than 1000 ml (3 donors). At 
the end of bypass, factor IX concentrate (375 to 500 IU) 
was added to the CPB circuit of 15 patients with preop- 
erative low prothrombin time (PT) values (less than 30%). 
Hemostasis during the operation had to be supported by 
giving fresh frozen plasma (n = 4), platelet concentrates 
(n = 5), or cryoprecipitate (n = 1) to 9 patients. Aprotinin 
was given (50,000 to 100,000 IU/kg) to 20 patients, 18 of 
whom were neonates. Our current strategy is to give 
aprotinin to all neonates, deeply cyanotic older infants, 
and all patients undergoing reoperation. During 1992 this 
routine was just being introdueed, which explains wby 
occasional neonates did not receive aprotinin. CPB time 
varied from 22 to 232 minutes (mean -+ SD* 105 + 43 
minutes). The heparin effect was neutralized by giving 
protamine (at first 2 mg/kg and then additional doses 
according to the activated clotting times). The postoper- 
ative stay at the intensive care unit varied from 1 to 36 
days (7.5 + 5.8 days). Of the 73 patients, 11 have died; 7 
patients died during the postoperative intensive care unit 
stay in intimate relation to the complex operation and 4 
patients died later. 
We recorded 51 parameters concerning the preopera- 
tive medical history, cardiac problems, anesthesia, opera- 
tion, and postoperative course from the patient records. 
In addition, 19 preoperative laboratory parameters were 
recorded. The preoperative screening of coagulation con- 
sisted of activated partial thromboplastin time (APTT), 
PT, and platelet count. After operation, APTT and PT 
were measured when clinically indicated. Hemoglobin, 
hematocrit, and platelet count were analyzed until the 
eighth postoperative day. 
Five clinical subgroups of patients were also analyzed. 
These were those who subsequently died, the neonates, 
and the tbree subgroups of cardiac defects. For the latter, 
a pediatric cardiologist divided the patients as to those 
with and those without cardiac failure (54 versus 17 
*Standard eviation. 
Table I. Cardiac defects and classification of 
operative procedures in the 73 infants 
Diagnosis n 
Simple 
Aortic stenosis 3 
Atrial septal defect 3 
Intermediate 
Atrioventricular septal defect 20 
VSD 11 
Complex 
Simple TGA 10 
Complex TGA (TGA + VSD) 8 
Total anomalous pulmonary venous drainage 3 
Left heart hypoplasia 2 
Univentricular heart connection 1 
Other 12 
TGA, Transposition f the great arteries; VSD, ventricular septal defect. 
patients), profound preoperative hypoxia (19 versus 53 
patients), and a cardiac defect with increased turbulence 
of blood flow (22 versus 50 patients). When the division 
was made, the cardiologist did not have knowledge of the 
postoperative bleeding or blood product use of the pa- 
tients. The subgroups of the cardiac defects were not 
mutually exclusive. The surgical procedures were also 
divided into categories of simple, intermediate, and com- 
plex. 
The drainage from chest tubes during the first 6 post- 
operative hours was taken as a measure of the postoper- 
ative bleeding. This arbitrary limit was chosen because 
later the secretion from the chest tubes gradually and 
variably turns from blood into a mixture of blood and 
serous exudate. The plasma dilution during and immedi- 
ately after CPB was calculated by the formuIa: 
(100 - Hctpreoperative ) • Hct t 
F = 100 
(100 - Hctt) • Hctpreoperative 
where Hct~ presents the lowest hematocrit value measured 
during CPB (maximal dilution) or the hematocrit value at 
the end of the operation (postoperative dilution), as 
Two-tailed Student's t test for independent samples and 
B test were used for comparisons and Spearman R 
correlation test was used to calculate correlation coeffi- 
cients. A value ofp < 0.05 was regarded as significant. 
The study protocol was approved by the ethics commit- 
tee of the Children's Hospital, University Central Hospi- 
tal of Helsinki. 
Results 
Bleeding. Of the 73 patients, only 1 patient had a 
recognizable bleeding complication. This patient 
underwent reoperat ion because of defective surgical 
hemostasis. Another  patient had, after repeated 
resuscitations necessitated by low cardiac output, 
gastrointestinal tract bleeding and laboratory evi- 
dence of disseminated intravascular coagulation. 
This patient died of these multiple complications. 
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Table II. Blood loss (mean +_ SD) by age and 
surgical difficu#y 
Blood loss 
(ml/kg) 
By age 
Neonates (n = 23) 10.0 + 9.6 
Older infants (n = 50) 10.8 + 5.4 
By surgical difficulty 
Simple (n = 6) 8.8 - 3.4 
Intermediate (n = 31) 11.3 _+ 3.9 
Complex (n = 36) 10.2 -+ 9.1 
None of the differences are statistically significant. 
The mean drainage from the chest tubes was 10 
ml/kg during the first 6 postoperative hours. It was 
less than 8 ml/kg (10% of the estimated mean blood 
volume of 80 ml/kg) in 33% of patients and less than 
20 ml/kg (25% of blood volume) in 96% of patients. 
The amount of drainage from chest tubes did not 
correlate with any of the tested clinical or laboratory 
parameters. The chest tube drainage was also ana- 
lyzed according to the complexity of the operation 
(Table II). No significant differences were found 
between simple, intermediate, and complex opera- 
tions. The drainage did not differ between the 
neonates and the older infants (Table II). 
Postoperative use of blood produets. During the 
intensive care unit stay three patients did not receive 
any blood products. RBCs were given to 68 (93%), 
whole blood transfusions to 10 (14%), platelet con- 
centrates to 20 (27%), and fresh frozen plasma to 8 
(11%) of the patients. The previously mentioned 
patient with disseminated intravascular coagulation 
also received factor IX concentrate and cryoprecip- 
itate. Of the 20 patients who received platelets, 13 
were neonates. Forty-three patients (59%) were 
treated throughout the intensive care unit stay with- 
out any blood product other than RBCs. Of these, 9 
were neonates (39% of all the neonates) and 34 
were older infants (68% oft all the older infants). 
To find possible preoperative and perioperative 
indicators of postoperative blood product need, the 
patient material was analyzed for associations be- 
tween the use of blood products and clinical and 
laboratory parameters (Table III). A further ap- 
proach was made by first dividing the patient series 
into clinical subgroups as described in the Patients 
and rnethods ection. Then the use of RBCs and 
platelet concentrates was studied in these subgroups 
(Table IV). 
The use of platelet concentrates but not RBCs 
was clustered in the neonates. Of the neonates 57% 
and of the older infants 14% received platelet 
concentrates (p < 0.001). In the search for a mech- 
anism for this, all the factors associated with the use 
of platelet concentrates in the patient series as a 
whole (Table III) were found to be more unfavor- 
able in the neonates than in the older infants (Table 
V). To test whether these factors (namely, CPB 
time, circulatory arrest ime, degree of hypothermia, 
dose of heparin, perioperative and postoperative 
dilution, preoperative platelet count, and hemato- 
crit value had any indicator value of subsequent 
platelet concentrates need for outside the neonatal 
period, the analysis was repeated after exclusion of 
the neonates (Table VI). The postoperative dilu- 
tion, preoperative hematocrit value, CPB time, and 
circulatory arrest time were significantly increased 
in the older infants receiving platelet concentrates 
when compared with these variables in the older 
infants who did not receive platelet concentrates. 
A new finding in the present study was the associa- 
tion between postoperative h modilution and later use 
of platelet concentrates and RBCs (Fig. 1). 
Discussion 
The first objective of the present study was to 
analyze the frequency and type of bleeding compli- 
cations. Somewhat surprisingly, such complications 
were rare. Only one patient had to undergo reop- 
eration because of excessive bleeding caused by a 
surgical defect in a vascular anastomosis. Also, 
general postoperative blood loss, measured as drain- 
age from chest ubes during the first 6 postoperative 
hours, was low and did not correlate with any of the 
tested parameters. 
Out studywas timulated by recent reports that 
recommended the use of fresh whole blood through- 
out the operation and postoperative period in in- 
fants undergoing heart operations 12' 14 and indi- 
cated no further need for transfusion therapy in 
these infants. 14 In their study Manno and associ- 
ates 12 found the mean 24-hour blood loss to be 96 
ml/kg (120% of blood volume) if reconstituted 
blood was used and 52 ml/kg (65% of blood volume) 
if fresh whole blood was used. They concluded that 
fresh blood should be used to achieve less bleeding 
in children younger than 2 years old. 12 The present 
study is a retrospective analysis, whereas the study 
by Manno and associates 12was prospective and 
randomized. In addition, we recorded chest tube 
drainage for only 6 hours. These differences make a 
direct comparison of the studies impossible. How- 
ever, in light of the figures reported by Manno and 
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Table III. Spearman R correlation coefficients and corresponding significance levels for use of RBCs and 
platelet concentrates and relevant clinical or Iaboratory parameters 
RBC transfusions Platelet transfusions 
R p Value R p Value 
Patient age -0.29 0.013 -0.43 <0.001 
CPB time 0.44 <0.001 0.33 0.005 
Aortic clamping time 0.41 <0.001 0.18 NS 
Arrest time 0.26 0.028 0.59 <0.001 
Degree of hypothermia -0.36 0.003 -0.42 <0.001 
Hemofiltration - 0.13 NS -0.17 NS 
Dosage of fentanyl per kilogram 0.06 NS 0.04 NS 
Dosage of protamine per kilogram 0.12 NS 0.08 NS 
Dosage of heparin per kilogram 0.27 0.022 0.30 0.011 
Maximal dilution -0.22 NS -0.27 0.020 
Postoperative dilution -0.38 0.001 -0.40 <0.001 
APq-T 0.43 0.001 0.25 NS 
PT -0.24 NS -0.24 NS 
Activated clotting tirne 0.02 NS 0.20 NS 
Platelet count -0.20 NS -0.30 0.010 
Hematocrit 0.27 0.021 0.52 <0.001 
Laboratory values refer to those measured preoperatively. Activated clotting time refers to the value at the end of the operaüon. NS, Not significant. 
Table IV. Relative use of RBCs and platelet 
concentrates (mean of whole patient series, 1.00) in 
different subgroups of patients 
RBC Platelet 
transfusions transfusions 
n Mean p Value Mean p Value 
Deceased 11 1.58 0.027 2.20 0.025 
Neonates 23 1.23 NS 2.00 0.001 
Hypoxia 19 1.31 NS 1.80 0.034 
Cardiac failure 54 0.90 NS 0.82 NS 
Turbulence* 22 0.81 NS 0.80 NS 
The p values calculated by two-tailed t test for independent samples. 
*Cardiac defeet with increased turbulence of blood flow. 
associates 12 we believe that our strategy of using 
blood component herapy after operation was asso- 
ciated with an acceptable and manageable amount 
of postoperative blood loss. 
It is our practice to use whole blood 20 to 28 hours 
after its donation for the CPB prime; the leftover 
content of the reserved 2 units are then used if 
needed during the operation for additional transfu- 
sions. This is essentially similar to the practice used 
by Jobes and coworkers, 14 who reported they could 
avoid further blood transfusions during and after 
operation even in neonates with this approach. In 
the present study this was clearly not the case: 12% 
of the patients received plasma or platelets, or both, 
during the operation and an additional 37% of 
patients needed these products during the intensive 
Table V. Comparison of neonates and older infants 
in respect o factors that correlated with use of 
platelet concuntrates 
Older 
Neonates infants 
(mean +_ SD) (mean + SD) p Value 
CPB time (min) 140 ± 45 89 + 30 <0.001 
Arrest time (min) 32 + 28 5 ± 15 <0.001 
Degree of hypothermia 16.0 ±- 1.5 17.9 ± 2.3 <0.001 
(o C) 
Dose of heparin 6.5 ± i.I 5.6 ± i.i 0.002 
(mg/kg) 
Maximal dilution (%) 33 + 14 51 + 15 <0.001 
Postoperative dilution 59 ± 17 90 ± 29 <0.001 
(%) 
Platelet count 315 ± 127 431 ± 104 <0.001 
(109m) 
Preoperative hematocrit 51 ± 7 39 ± 6 <0.001 
(%) 
care unit stay. However, the clinical significance of 
this difference cannot be evaluated further, because 
in the present patient series the indications for indi- 
vidual postoperative transfusions were not predeter- 
mined but were partially dependent on the subjective 
judgment of the physician on duty. Sutfice it to say that 
when the hemostatic apacity of the patient was judged 
subjectively by the surgeon and the anesthesiologist, 
the use of fresh whole blood during the operation did 
not abolish the frequent need for further blood prod- 
ucts during and after the operation. 
The use of factor IX concentrate in the prime for 
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Table VI. Factors that correlated with use of platelet concentrates in whole patient series studied after 
exclusion of neonates 
Platelet concentrates* No platelet concentrates* 
(mean + SD) (mean + SD) p Value 
No. of patients 7 43 
CPB time (min) 119 + 24 84 _+ 29 0.004 
Arrest ime (min) 16 + 7 0 _+ 0 <0.001 
Degree of hypothermia (° C) 16.4 -+ 1.5 18.2 -+ 2.4 NS 
Dosage of heparin (mg/kg) 5.8 + 0.9 5.6 _+ 1.1 NS 
Postoperative dilution (%) 70 -+ 24 93 -+ 29 0.048 
Maximal dilution (%) 46 _+ 19 52 -+ 14 NS 
Preoperative h matocrit (%) 45 _+ 8 38 _+ 5 0.001 
Platelet count  (106/L) 433 -+ 91 431 -+ 107 NS 
NS, Not significant. 
*The 50 patients are divided into those who received platelets and those who did not. 
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Fig. 1. Hemodilution factor F (mean _+ SD) during and 
immediately after operation in patients who received 
platelet concentrates (PL+) and in those who did not 
(PL-). NS, Not significant. 
the patients with low preoperative PT values is 
based on our clinical impression that this approach 
decreases the bleeding from the operative field with 
no experience of side effects. We prefer to use factor 
IX concentrate as the first choice of clotting factor 
concentrates because it is concentrated also for 
prothrombin and factor X.  Cryoprecipitate would 
have the advantage of containing more fibrinogen, 
which may be of significance specially in the neo- 
nates, a3 However, in the absence of controlled stud- 
ies between these two preparations, the question of 
superiority remains open. 
The second objective of the study was to find 
clinical risk factors of bleeding tendency and indica- 
tors of blood product need. Regarding the chest 
tube drainage, the analysis was unrewarding. No 
significant associations between clinical parameters 
and the blood drainage could be found. However, 
the blood product use was found to correlate with 
several preoperative and perioperative clinical and 
laboratory parameters. This discrepancy of blood 
component use and recorded bleeding is explained 
by the fact that bleeding could be recorded only 
during immediate postoperative hours, whereas trans- 
fusions were analyzed for the whole period of intensive 
care. Further, bleeding is only one mechanism for 
blood product need. For example, platelets are con- 
sumed by infections and in the CPB circuit. 2In infants 
the need for RBCs to replace the blood lost in blood 
samples makes RBC transfusions almost unavoidable 
in pediatric ardiac operations, tz 
The most interesting findings of the blood prod- 
uct use were those concerning the use of platelet 
concentrates. Platelets were given to 27% of pa- 
tients, which is in accordance with the reported 
corresponding figures of between 19% and 24% for 
adults.6, i0 Platelet use during intensive care was 
clustered in two subgroups of patients, the neonates 
and those with cyanotic ardiac defects, as could be 
expected) 4 Further analysis demonstrated the mul- 
tifactor background of platelet need in the neonates. 
Long CPB time, deeper hypothermia n association 
with circulatory arrest, larger dosages of heparin, 
more extensive plasma dilution during CPB, and 
high preoperative hematocrit were more pro- 
nounced in the neonates than in the older infants. 
Further, the hemostatic system of the neonate is 
immature and thus prone to disturbances.a6-18 Apro- 
tinin was given almost exclusively to neonates, but 
this could not abolish the more frequent use of 
platelets in the neonates. 
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After exclusion of the neonates from the data, 
platelet use was still associated with long CPB time, 
circulatory arrest, preoperatively high hematocrit, 
and extensive dilution after CPB. Cyanotic heart 
defects are known to be associated with both high 
hematocrit and increased bleeding. However, it was 
a new finding that high hematocrit value, irrespec- 
tive of whether it was caused by cyanosis or a 
neonatal age, was associated with platelet use. The 
mechanism ay be that those patients with high 
preoperative hematocrit value had greater elative 
reduction in hematocrit value during CPB. This 
resulted in greater dilution of all plasma proteins 
including elotting factors during and immediately 
after the operation. 15These results indicate that it 
should be prospectively studied as to whether those 
patients with a high hematocrit value could have a 
higher target hematocrit value during and after 
CPB, bearing in mind the potential negative rheo- 
logic effects. 
In summary, it was shown that the use of fresh 
whole blood in the CPB prime did not abolish the 
occasional need for perioperative platelet concen- 
trates, fresh frozen plasma, and clotting factor con- 
centrates. According to our experience it seems 
rational to make a fresh whole blood reservation of 
2 units for CPB and then manage the occasional 
further perioperative transfusion eeds with blood 
components. On the other hand, postoperative 
transfusion requirements could easily be met with 
conventional b ood component therapy. Sixty-eight 
percent of patients between 1month and 1 year old 
could be treated without any postoperative transfu- 
sion other than RBC supplementation. I  the neo- 
nates, platelet concentrates or fresh frozen plasma, 
or both, were used in 61% of the patients. This 
transfusion practice was associated with no severe 
complications caused by bleeding and the general 
postoperative blood loss was acceptable. According 
to our experience, postoperative blood component 
therapy can safely be used throughout pediatric 
cardiac operations. 
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